MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Malaria vaccine plant takes a gamble
In a nondescript office park tucked between a hospital and a strip mall thrive hundreds of thousands of the most infectious malaria-carrying mosquitoes ever born. They will be dissected for the motherlode that they carry -- baby malaria parasites, fodder for a new malaria vaccine.
Sanaria, PATH Malaria Vaccine Initiative Open Manufacturing Facility For Producing World’s First “Whole-Parasite” Malaria Vaccine
Sanaria Inc. and the PATH Malaria Vaccine Initiative today officially opened a one-of-a-kind clinical manufacturing facility to produce a vaccine that uses a weakened form of the malaria parasite to fight a disease that annually kills more than one million people, most of them African children.
New front launched in war on malaria
With $29.3M from the Gates Foundation, Rockville company opens plant today.
Fred Binka, Sanaria Advisory Board Member, featured in Newsweek
Read the full Newsweek article: “Giving Globally: The Search for Solutions“
Sanaria featured in National Geographic magazine
Read the full story: Bedlam in the Blood, Malaria (Membership required). NatGeo Article
Sanaria featured in ‘Kill or Cure’ documentary
Kill or Cure? The Malaria Vaccine takes viewers into the starkly different worlds of two cutting-edge investigators who may be moving us tantalizingly close to an achievement unheard of in the history of immunizations - an effective vaccine against a parasitic disease.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.